在小鼠原位胰腺癌模型中进行血管生成的生物发光成像。
Bioluminescence imaging of angiogenesis in a murine orthotopic pancreatic cancer model.
机构信息
Hirshberg Laboratory for Pancreatic Cancer Research, Department of Surgery, UCLA Center for Excellence in Pancreatic Diseases, David Geffen School of Medicine, University of California-Los Angeles, 675 Charles E. Young Drive South, Los Angeles, CA 90095, USA.
出版信息
Mol Imaging Biol. 2010 Dec;12(6):570-5. doi: 10.1007/s11307-010-0310-4.
PURPOSE
Angiogenesis is essential for physiological processes as well as for carcinogenesis. New approaches to cancer therapy include targeting angiogenesis. One target is VEGF-A and its receptor VEGFR2. In this study, we sought to investigate pancreatic cancer angiogenesis in a genetically modified VEGFR2-luc-KI mouse.
PROCEDURES
Live in vivo bioluminescence imaging of angiogenesis was performed continuously until sacrifice in subcutaneous tumors as well as in orthotopically transplanted tumors. Tumor tissue was immunostained for CD-31 and VEGFR2.
RESULTS
Peritumoral angiogenesis measured by light emission was detected beginning at week 3 following subcutaneous injection. In the orthotopic model, light emission began at day 4, which likely corresponds to wound healing, and continued throughout the experimental period during tumor growth. Peritumoral CD-31 vessel- and VEGFR2-staining were positive.
CONCLUSIONS
The VEGFR2-luc-KI mouse is a valuable tool to demonstrate tumor angiogenesis and seems to be suitable to evaluate anti-angiogenic approaches in pancreatic cancer.
目的
血管生成对于生理过程以及致癌作用都是必不可少的。癌症治疗的新方法包括针对血管生成。一个靶点是 VEGF-A 和它的受体 VEGFR2。在这项研究中，我们试图在一个基因改造的 VEGFR2-luc-KI 小鼠中研究胰腺癌的血管生成。
方法
对皮下肿瘤和原位移植肿瘤进行连续的活体生物发光成像，以观察血管生成。肿瘤组织用 CD-31 和 VEGFR2 进行免疫染色。
结果
在皮下注射后第 3 周开始通过发光测量到肿瘤周围的血管生成。在原位模型中，发光始于第 4 天，可能与伤口愈合有关，并在肿瘤生长期间的整个实验期间持续。肿瘤周围的 CD-31 血管和 VEGFR2 染色均为阳性。
结论
VEGFR2-luc-KI 小鼠是一种用于展示肿瘤血管生成的有价值的工具，似乎适合用于评估胰腺癌的抗血管生成方法。
Zotero 插件